Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Position Reduced by Pitcairn Co.

Pitcairn Co. lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 7.5% during the 4th quarter, Holdings Channel reports. The institutional investor owned 890 shares of the biopharmaceutical company’s stock after selling 72 shares during the quarter. Pitcairn Co.’s holdings in Regeneron Pharmaceuticals were worth $634,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in REGN. Norges Bank acquired a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth $802,036,000. Amundi increased its position in Regeneron Pharmaceuticals by 45.8% in the 4th quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company’s stock worth $1,138,074,000 after purchasing an additional 487,489 shares during the last quarter. Loomis Sayles & Co. L P raised its stake in shares of Regeneron Pharmaceuticals by 33.4% during the 4th quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company’s stock worth $1,122,168,000 after purchasing an additional 393,997 shares in the last quarter. Proficio Capital Partners LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 92,865.3% during the 4th quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company’s stock valued at $156,284,000 after buying an additional 219,162 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Regeneron Pharmaceuticals by 6.8% in the 4th quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company’s stock valued at $1,726,940,000 after buying an additional 155,369 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 6.1 %

Shares of Regeneron Pharmaceuticals stock opened at $573.45 on Friday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $572.00 and a 52-week high of $1,211.20. The firm has a market capitalization of $62.69 billion, a PE ratio of 14.98, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The company’s fifty day moving average price is $676.70 and its two-hundred day moving average price is $781.68.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. The business had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $11.86 earnings per share. On average, analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were issued a $0.88 dividend. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.61%. Regeneron Pharmaceuticals’s payout ratio is presently 2.30%.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on REGN shares. JPMorgan Chase & Co. reduced their target price on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an “overweight” rating for the company in a research note on Monday, March 31st. Robert W. Baird decreased their price objective on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a report on Wednesday, February 5th. Leerink Partners upgraded Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and raised their target price for the company from $762.00 to $834.00 in a report on Wednesday, February 5th. Piper Sandler decreased their price target on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a research note on Monday, January 27th. Finally, Canaccord Genuity Group downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $966.88.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.